Prize - healthylife7.com

Browsing: Prize

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

By healthylife7August 11, 20260

BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion. Shares are up 26.2% year to date and 18.6% over one year, though still down 35.3% over five years. What changed is the P&L

What's Hot

Trouble losing weight? It might be your gut microbes, not your genes

Recognize the Connections

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Browsing: Prize

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Trouble losing weight? It might be your gut microbes, not your genes

Recognize the Connections

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Tropical depression could form this week. See Pensacola impact

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

What do the Middle Ages tell us about mental health then and now? VCU historian Leigh Ann Craig has answers

Fitness

Trouble losing weight? It might be your gut microbes, not your genes

Recognize the Connections

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Health

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

Subscribe to Updates

What's Hot

Browsing: Prize